Resource library

Presentations

Videos & Animations

Featured
Why is there a copay for breast cancer medicine?
Why is there a copay for breast cancer medicine?
Demand first dollar coverage for your medicines
Demand first dollar coverage for your medicines
Why is there a copay for cancer medicine?
Why is there a copay for cancer medicine?
Why is there a copay for insulin?
Why is there a copay for insulin?
Why is there a copay for asthma inhalers?
Why is there a copay for asthma inhalers?
The Massachusetts Paradox
The Massachusetts Paradox
A note of thanks to the FDA
A note of thanks to the FDA
Protect American Innovation
Protect American Innovation
The Investor’s Paradox
The Investor’s Paradox
Affordability & Innovation
Affordability & Innovation
Inventing new medicines is a long climb
Inventing new medicines is a long climb
What is Abbie Saving For?
What is Abbie Saving For?
The Value of Medicines
The Value of Medicines

Research

Featured
No More Freeriding on the Great American Drug Deal
No More Freeriding on the Great American Drug Deal
Valuing Healthcare Innovation
Valuing Healthcare Innovation
Foreign countries rely on flawed and outdated HTA or ”value assessment” methods to justify low prices for medicines
Foreign countries rely on flawed and outdated HTA or ”value assessment” methods to justify low prices for medicines
Price Controls Hinder Treatment Access in Medicare Part D
Price Controls Hinder Treatment Access in Medicare Part D
Consumers sound alarm: state price controls will limit access without lowering patient costs
Consumers sound alarm: state price controls will limit access without lowering patient costs
Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold
Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold
NEW REPORT: Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
NEW REPORT: Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
Value in Health: It’s time to reconsider the three percent discount rate.
Value in Health: It’s time to reconsider the three percent discount rate.
Is the price right? Paying for value today to get more value tomorrow
Is the price right? Paying for value today to get more value tomorrow
When simpler isn’t better: a case for generalized cost-effectiveness analysis
When simpler isn’t better: a case for generalized cost-effectiveness analysis
Why the discount rate is exciting!
Why the discount rate is exciting!
The American Journal of Managed Care: Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C
The American Journal of Managed Care: Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C
Getting the math right when measuring the value of new medicines
Getting the math right when measuring the value of new medicines
Do Cost-Effectiveness Analyses Account for Drug Genericization?
Do Cost-Effectiveness Analyses Account for Drug Genericization?

Letters & Public Comments

Featured
Public Comment: Accelerate Safe and Effective Drug Access, PDUFA III
Public Comment: Accelerate Safe and Effective Drug Access, PDUFA III
Public Comment: Demand Equitable Contribution to Biomedical Innovation
Public Comment: Demand Equitable Contribution to Biomedical Innovation
A Letter to Senate HELP Committee Chairman Bill Cassidy on Preserving and Modernizing the FDA
A Letter to Senate HELP Committee Chairman Bill Cassidy on Preserving and Modernizing the FDA
Public Comment: End Unfair Trade Practices in Drug Pricing
Public Comment: End Unfair Trade Practices in Drug Pricing
Public Comment: Use tariff and market access tools to force OECD countries to pay their fair share for medical innovation
Public Comment: Use tariff and market access tools to force OECD countries to pay their fair share for medical innovation
Open letter to President Trump from biopharma innovators, investors, and patient advocates regarding proposed FDA budget and personnel cuts.
Open letter to President Trump from biopharma innovators, investors, and patient advocates regarding proposed FDA budget and personnel cuts.
Defending the NIH, the NSF, and the foundation of American science
Defending the NIH, the NSF, and the foundation of American science
Public Comment: Allow Medicare to cover anti-obesity medications (AOMs) and strengthen patient protection “guardrails” through better oversight of Medicare Advantage Part D (MAPD) plans.
Public Comment: Allow Medicare to cover anti-obesity medications (AOMs) and strengthen patient protection “guardrails” through better oversight of Medicare Advantage Part D (MAPD) plans.
Public Comment: Share savings from Medicare price setting with patients not plans
Public Comment: Share savings from Medicare price setting with patients not plans
NEW LETTER: Investors and executives urge the Congressional Budget Office to adopt changes to its modeling
NEW LETTER: Investors and executives urge the Congressional Budget Office to adopt changes to its modeling
Sign-on letter: Why Fixing the IRA Matters to all of us
Sign-on letter: Why Fixing the IRA Matters to all of us
Public Comment: Protect patients when implementing the price setting provisions of the Inflation Reduction Act
Public Comment: Protect patients when implementing the price setting provisions of the Inflation Reduction Act
Mifepristone ruling: biotech leaders defend FDA's autonomy and authority
Mifepristone ruling: biotech leaders defend FDA's autonomy and authority
Public Comment: Exemptions of the Inflation Reduction Act fail to provide adequate protections
Public Comment: Exemptions of the Inflation Reduction Act fail to provide adequate protections

Media

Featured
8 Ways to Modernize the FDA
8 Ways to Modernize the FDA
Journal of Comparative Effectiveness Research: Generalized cost–effectiveness analysis - charting a path forward for measuring the societal value of medical technologies
Journal of Comparative Effectiveness Research: Generalized cost–effectiveness analysis - charting a path forward for measuring the societal value of medical technologies
The Evidence Base: New framework proposed for valuing medicines’ broader societal impact
The Evidence Base: New framework proposed for valuing medicines’ broader societal impact
R&D World: How much does the pharma industry spend on R&D anyway? Probably more than you thought
R&D World: How much does the pharma industry spend on R&D anyway? Probably more than you thought
USA Today: Mammograms can prevent breast cancer deaths. But many skip screening due to cost.
USA Today: Mammograms can prevent breast cancer deaths. But many skip screening due to cost.
Cambridge Day: Health care costs keep rising, but biopharma is not the enemy
Cambridge Day: Health care costs keep rising, but biopharma is not the enemy
AI can make it easier to discover new medicines – but Congress is making it harder
AI can make it easier to discover new medicines – but Congress is making it harder
STAT News: The world is relying on the United States to get value-based drug pricing right
STAT News: The world is relying on the United States to get value-based drug pricing right
5 ways Biden’s SOTU could advance biotech affordability and innovation
5 ways Biden’s SOTU could advance biotech affordability and innovation
Bucks County Herald: Drug price controls hurt investment in new medicines
Bucks County Herald: Drug price controls hurt investment in new medicines
Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus</a>
Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus
The Well News: Ensuring Medicare Rx Price Negotiations Help Patients
The Well News: Ensuring Medicare Rx Price Negotiations Help Patients
Xtelligent Healthcare: The Importance of Accurately Measuring the Value of New Medications
Xtelligent Healthcare: The Importance of Accurately Measuring the Value of New Medications
PharmaExec: The Value of Care - Q&amp;A With Peter Rubin, Executive Director at No Patient Left Behind
PharmaExec: The Value of Care - Q&A With Peter Rubin, Executive Director at No Patient Left Behind

Community Quest

Featured
The Quest to Cure Muscular Dystrophy
The Quest to Cure Muscular Dystrophy
The Quest to Treat Mental Health
The Quest to Treat Mental Health
The Quest to Defeat Lymphoma
The Quest to Defeat Lymphoma
The Quest to Beat Dementia
The Quest to Beat Dementia
The Quest to Treat Blindness
The Quest to Treat Blindness
The Quest to Cure Alzheimer’s
The Quest to Cure Alzheimer’s
The Quest to Defeat Pancreatic Cancer
The Quest to Defeat Pancreatic Cancer
The Quest to Cure Wet AMD
The Quest to Cure Wet AMD
The Quest to Defeat Myositis
The Quest to Defeat Myositis
The Quest to Cure Leukemia
The Quest to Cure Leukemia
The Quest to Beat Epilepsy
The Quest to Beat Epilepsy
The Quest to Treat Autoimmune Nephropathy
The Quest to Treat Autoimmune Nephropathy
The Quest to Beat Lung Cancer
The Quest to Beat Lung Cancer
The Quest to Combat Liver Disease
The Quest to Combat Liver Disease

Op-eds and blog posts

Featured
8 Ways to Modernize the FDA
8 Ways to Modernize the FDA
Journal of Comparative Effectiveness Research: Generalized cost–effectiveness analysis - charting a path forward for measuring the societal value of medical technologies
Journal of Comparative Effectiveness Research: Generalized cost–effectiveness analysis - charting a path forward for measuring the societal value of medical technologies
Cambridge Day: Health care costs keep rising, but biopharma is not the enemy
Cambridge Day: Health care costs keep rising, but biopharma is not the enemy
STAT News: The world is relying on the United States to get value-based drug pricing right
STAT News: The world is relying on the United States to get value-based drug pricing right
5 ways Biden’s SOTU could advance biotech affordability and innovation
5 ways Biden’s SOTU could advance biotech affordability and innovation
Bucks County Herald: Drug price controls hurt investment in new medicines
Bucks County Herald: Drug price controls hurt investment in new medicines
Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus</a>
Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus
The Well News: Ensuring Medicare Rx Price Negotiations Help Patients
The Well News: Ensuring Medicare Rx Price Negotiations Help Patients
Measuring the damage: IRA’s impact on small molecule drug development
Measuring the damage: IRA’s impact on small molecule drug development
The Well News: Misguided Rating Cancels Rare Disease Patients
The Well News: Misguided Rating Cancels Rare Disease Patients
RealClearHealth: For Two Years, Australia Failed People With Cystic Fibrosis; It Can’t Happen Again
RealClearHealth: For Two Years, Australia Failed People With Cystic Fibrosis; It Can’t Happen Again
The Well News: Fix BBB’s Rx Provisions so Patients Aren’t Stuck With High Bills and More Needles
The Well News: Fix BBB’s Rx Provisions so Patients Aren’t Stuck With High Bills and More Needles
Timmerman Report: Aducanumab &amp; the Alzheimer’s Moonshot: What Would It Be Worth to Keep Your Mind?
Timmerman Report: Aducanumab & the Alzheimer’s Moonshot: What Would It Be Worth to Keep Your Mind?
PBMs: The Secretive Middlemen for Insurance and Drug Companies
PBMs: The Secretive Middlemen for Insurance and Drug Companies

Community Outreach

Press Releases

Featured
New Analysis Reveals Foreign Countries’ Flawed Value Assessments Undervalue Innovative Medicines by up to 94%
New Study Highlights Challenges in Medicare Part D Treatment Access and Major Concerns over Inflation Reduction Act
New Study Reveals Widespread Concern over Prescription Price Controls, Costs, and Access
NPLB Statement on Murder of Brian Thompson
New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines
Getting the Math Right: The Growing Movement to Improve How Medicines Are Valued Will Take Center Stage at ISPOR 2024
APRIL FOOLS’: FTC Announces Zero Copay Mandate
Investors and Innovators Representing more than $309B in Biotech Assets and 624 New Drugs in Development Urge the Congressional Budget Office to Update its Drug R&D Policy Impact Model
Statement / Background Info Regarding the Institute for Clinical and Economic Review’s (ICER) Proposed Value Assessment Framework
Innovative Medicines Provide Greater Value to Patients and Society than Previously Calculated
NPLB Statement on ICER’s Flawed Value Assessment Framework
New NPLB Video Illustrates Why Patients Deserve Better Math to Value New Drugs
NPLB Gets Animated: Roadmap to Patient Affordability and Innovation
One Thousand Investors, Researchers, Patients, & Innovators Sign Letter Urging Critical Fixes to Senate Rx Bill

We’re building support across the biotech ecosystem

BECOME A FIRST RESPONDER & THOUGHT PARTNER

Sign up to receive action alerts. Help protect access to lifesaving medicines & preserve innovation for those still waiting for a cure.